Highlights of This Issue 753

SPECIAL FEATURES

CCR Translations

Predictive Biomarkers to Anti-VEGF Therapy: Progress toward an Elusive Goal
Rekha Gyanchandani and Seungwon Kim
See article, p. 929

Molecular Pathways

Molecular Pathways: Multimodal Cancer-Killing Mechanisms Employed By Oncolytic Vesiculoviruses
Douglas J. Mahoney and David F. Stojdl

Review

The Definition of Primary and Secondary Glioblastoma
Hiroko Ohgaki and Paul Kleihues

HUMAN CANCER BIOLOGY

Lactate Dehydrogenase B Is Required for the Growth of KRAS-Dependent Lung Adenocarcinomas
Mark L. McCleland, Adam S. Adler, Laura Deming, Ely Cosino, Leslie Lee, Elizabeth M. Blackwood, Margaret Solon, Janet Tao, Li Li, David Shames, Erica Jackson, William F. Forrest, and Ron Firestein

Reciprocal Interactions between Tumor-Associated Macrophages and CD44-Positive Cancer Cells via Osteopontin/CD44 Promote Tumorigenicity in Colorectal Cancer
Guanhua Rao, Hongyi Wang, Baowei Li, Li Huang, Danfeng Xue, Xiaohui Wang, Hailing Jin, Jun Wang, Yushan Zhu, Youyong Lu, Lei Du, and Quan Chen

SHP2 Is Overexpressed and Inhibits pSTAT1-Mediated APM Component Expression, T-cell Attracting Chemokine Secretion, and CTL Recognition in Head and Neck Cancer Cells
Michael S. Leibowitz, Raghvendra M. Srivastava, Pedro A. Andrade Filho, Ann Marie Egloff, Lin Wang, Raja R. Seethala, Soldano Ferrone, and Robert L. Ferris

CANCER THERAPY: PRECLINICAL

Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer

Influence of Human OATP1B1, OATP1B3, and OATP1A2 on the Pharmacokinetics of Methotrexate and Paclitaxel in Humanized Transgenic Mice
Evita van de Steeg, Anita van Esch, Els Wagenaar, Kathryn E. Kenworthy, and Alfred H. Schinkel

Blocked Autophagy Using Lysosomotropic Agents Sensitizes Resistant Prostate Tumor Cells to the Novel Akt Inhibitor AZD5363
Francois Lamoureux, Christian Thomas, Claire Crafter, Masafumi Kumano, Fan Zhang, Barry R. Davies, Martin E. Geave, and Amina Zoubeidi

Caspase-Independent Cell Death Is Involved in the Negative Effect of EGF Receptor Inhibitors on Cisplatin in Non–Small Cell Lung Cancer Cells
Hirohito Yamaguchi, Jennifer L. Hsu, Chun-Te Chen, Ying-Nai Wang, Ming-Chuan Hsu, Shih-Shin Chang, Yi Du, How-Wen Ko, Roy Herbst, and Mien-Chie Hung

Development and Characterization of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma Tumorgrafts
Topotecan and Doxorubicin Combination to Treat Recurrent Ovarian Cancer: The Influence of Drug Exposure Time and Delivery Systems to Achieve Optimum Therapeutic Activity
Nilesh A. Patankar, Julia Pritchard, Mariska van Grinsven, Maryam Osooly, and Marcel B. Bally

DNA Methylation as an Adjunct to Histopathology to Detect Prevalent, Inconspicuous Dysplasia and Early-Stage Neoplasia in Barrett’s Esophagus
Muhammad A. Alvi, Xinxue Liu, Maria O’Donovan, Richard Newton, Lorenz Wernisch, Nicholas R. Shannon, Kareem Shariff, Massimiliano di Pietro, Jacques J.G.H.M. Bergman, Krish Ragunath, and Rebecca C. Fitzgerald

The Immune Signature of CD8+CCR7+ T Cells in the Peripheral Circulation Associates with Disease Recurrence in Patients with HNSCC
Malgorzata Czystowska, William Gooding, Miroslaw J. Szczepanski, Andres Lopez-Abaitero, Robert L. Ferris, Jonas T. Johnson, and Theresa L. Whiteside

A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma
David A. Reardon, Morris D. Groves, Patrick Y. Wen, Louis Nabors, Tom Mikkelson, Steve Rosenfeld, Jeffrey Raizer, Jorge Barriuso, Roger E. McLendon, Bo Ma, C. Martin Curtis, Mohammed M. Dar, and Johann de Bono

First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies

Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab
Priti S. Hegde, Adriam M. Jubh, Dafeng Chen, Nicole F. Li, Y. Gloria Meng, Coen Bernards, Rebecca Elliott, Stefan J. Scherer, and Daniel S. Chen

Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy
Reda Z. Mahfouz, Ania Jankowska, Qiteb El-Brahem, Xiaoerong Gu, Valeria Visconte, Ali Tabarrosi, Pramod Terse, Joseph Covey, Kenneth Chan, Yonghua Ling, Kory J. Engelke, Mikhail A. Sekeres, Ramon Tiu, Jaroslav Maciejewski, Tomas Radioyevitch, and Yogen Saunthararajah

Correction: Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies
Reda Z. Mahfouz, Ania Jankowska, Qiteb El-Brahem, Xiaoerong Gu, Valeria Visconte, Ali Tabarakos, Pramod Terse, Joseph Covey, Kenneth Chan, Yonghua Ling, Kory J. Engelke, Mikhail A. Sekeres, Ramon Tiu, Jaroslav Maciejewski, Tomas Radioyevitch, and Yogen Saunthararajah
ABOUT THE COVER

The image displays a human prostate cell line (PC-3) that has been stained with antibodies against the autophagy marker Light Chain 3 (LC3; green) after rapamycin treatment. During autophagy, LC3-I is converted to LC3-II through lipidation by a ubiquitin-like system involving Atg7 and Atg3 that allows for LC3 to become associated with autophagic vesicles, as shown by green punctea. Tumor cell nuclei are visualized by DAPI (blue). For details, see the article by Lamoureux and colleagues on page 833 of this issue.